MaxCyte and Wugen Enter Strategic Platform License to Accelerate Clinical Development and Commercial Manufacturing of Wugen’s Allogeneic Cell Therapies

On January 30, 2024, MaxCyte is aThe World's Leading Cell Engineering Solutions Provider, providing empowerment platform technology,Advance the Early Research, Clinical Development, and Commercialization of Next-Generation Innovative Cell Therapies，Wugen is a clinical-stage biotechnology company developing universal cell therapies.Blood and Solid Tumors, Both Announce Signing of Strategic Platform License (SPL).

Under the terms of the agreement, Wugen will obtain non-exclusive clinical and commercial rights to MaxCyte's Flow Electroporation® technology and ExPERT™ platform, and MaxCyte will receive corresponding licensing fees and related project revenue.。

Wugen is developingNext-Generation "Off-the-Shelf" Immunological Memory NK Cell Therapy and CAR-T Cell Therapy for Cancer Treatment，WugenThe cell therapy under study is derived from healthy donors and further engineered to enhance its ability to eliminate cancer cells.WU-CART-007 is a CD7-targeted CAR-T cell therapy currently undergoing global Phase 1/2 clinical trials for the treatment of adolescents and adults.Relapsed/Refractory T-CellAcute Lymphoblastic Leukemia(T-ALL) or Lymphoblastic Lymphoma (T-LBL)WU-CART-007 has received approval from the U.S. FDA.Fast Track Designation and Pediatric Rare Disease Designation, for the treatment of R/R T-ALL/LBL.

Maher Masoud, President and Chief Executive Officer of MaxCyteSaid: "As WU-CART-007 transitions to the ExPERT platform and continues to make clinical progress, we are able to provide efficient and seamless support for scaling up to large-scale production. Through collaboration with MaxCyte, Wugen can maximize the dose output per production run for late-stage clinical development and potential commercialization."

Kumar Srinivasan, President and CEO of Wugen"We are thrilled to partner with MaxCyte as an exciting step forward in our mission to develop breakthrough treatments for refractory cancers. This partnership brings us closer to delivering potentially life-saving treatments to patients with limited options. With MaxCyte’s expertise, we can accelerate the progress of key development stages and make a significant impact on patients’ lives."

MaxCyte's ExPERT™ product portfolio is the next-generation leading clinically validated electroporation technology, applied in complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability, and advanced performance, the ExPERT™ platform provides top-tier capabilities for the next generation of biological and cell therapies.

InMaxCyte, we maximize the potential of cells to improve patients' health by optimizing cell engineering technology.Through20Years of time,MaxCyteBuilt a first-class technology platform, optimized the transfection process, enhanced professional capabilities, and achieved solutions that surpass existing technologies.MaxCyteTheExPERT™The platform is based on itsFlow Electroporation®Technology, aimed at supporting rapid developmentThe cell therapy market, in the high-growth phase of the cell therapy field, encompasses comprehensive applications from discovery, development to the commercialization of next-generation cell-based drugs.MaxCyteTheExPERTProduct series include:Four Instruments, NamelyATx™、STx™、GTx™AndVLx™, a series of proprietary related processing components or single-use products, and software protocols, all products are protected by global intellectual property rights.By providing partners with appropriate technology and support, aiming to help partners enhance their development in the life and health field.2023Year,MaxCyteSupport empowered the world's first use of electric transfer andCRISPR/Cas9Gene Editing TherapyCASGEVYTMListed in the UK and US.

Wugen is a clinical-stage biotechnology company dedicated to developing next-generation "off-the-shelf" memory NK (Natural Killer) cell therapies and CAR-T cell therapies for cancer treatment. Wugen leverages its proprietary technology platform and deep expertise in genomic engineering to pioneer a new class of memory NK cell and CAR-T cell therapies aimed at treating both hematologic and solid malignancies.